MacroGenics Q2: $327M Pro Forma Cash, Gilead Option Exercise, Pipeline Advances
MGNX has more than doubled off its 52-week low of $1.29.
Summary
MacroGenics reported Q2 results with $32.8M revenue and $19.5M net income, highlighted by a $327M pro forma cash position and Gilead's $10M option exercise.
Key Events · Earnings and Guidance · MGNX
-
Q2 Revenue Miss, Net Income Positive
Revenue of $32.8M missed consensus of $67.5M, but net income of $19.5M was driven by $89.2M income from discontinued operations related to the manufacturing sale.
-
Pro Forma Cash $327M, Runway Through 2028
Pro forma cash, cash equivalents, and marketable securities totaled $327M as of June 30, 2026, including $119.6M from Bora, $24.5M Sanofi milestone, and $10M Gilead option exercise.
-
Gilead Option Exercise Triggers $10M
Gilead exercised its option to license a preclinical bispecific program under the 2022 collaboration, triggering a $10.0M payment to MacroGenics.
-
Pipeline Advances: MGC030 and MGD032
MGC030 IND cleared ahead of schedule with first patient expected in Q3 2026; MGD032 nominated as next-generation TCE advancing to IND-enabling studies.
Analysis · MGNX · Life Sciences
MacroGenics reported Q2 revenue of $32.8M, missing consensus by over half, but posted net income of $19.5M driven by the $122.5M manufacturing sale. The company's pro forma cash position of $327M extends runway through 2028, and a new $10M milestone from Gilead's option exercise adds near-term capital. Pipeline updates include MGC030 IND clearance and MGD032 nomination, positioning the company for multiple clinical catalysts.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MGNX was trading at $3.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $259.3M. The 52-week trading range was $1.29 to $5.08. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.